FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379285891> ?p ?o ?g. }

• W4379285891 endingPage "TPS624" @default.
• W4379285891 startingPage "TPS624" @default.
• W4379285891 abstract "TPS624 Background: According to advanced neoadjuvant chemotherapy (NACT), which dual HER2 blockage in HER2+ BC and adding carboplatin or immunotherapy in triple-negative breast cancer (TNBC) increased pathologic complete response (ypCR) rates up to 68% and 80%. Because ypCR patients showed better survival, the indications for NACT have expanded to early BC and the expected ypCR rate has increased. Therefore, it may be reasonable to consider omitting surgery in cases with excellent responses to NACT. Several recent retrospective studies and pilot prospective studies have reported axillary pathologic complete response (ApCR) is highly correlated with breast pathologic complete response (BpCR) in HER2+ or TNBC after NACT. The current report describes the design of omission of sentinel lymph node biopsy (SLNB) after NACT in HER2+ or TNBC patients with excellent response. Similarly, EUBREAST-01 (NCT04101851) study is ongoing omission of sentinel lymph node biopsy (SLNB) after NACT in HER2+/TNBC with radiologic complete remission and a BpCR. Methods: The ASLAN trial is a prospective, multicenter, single-arm, clinical study. Five tertiary care hospitals in South Korea are participating. Inclusion criteria: women aged 20-69; cT1-3N0-1M0; HER2+ or TNBC (defined by ER-negative (< 10% positive cells in IHC) and PgR-negative (< 10% positive cells in IHC)); expected complete remission at physical examination and radiological expected Tumor size ≤ 2cm or non-mass enhancement ≤ 4cm at breast MRI after standard NACT; planned breast conserving surgery (BCS) with whole-breast irradiation; ECOG performance status 0-1. Exclusion criteria: SLNB before NACT; previous axillary surgery; bilateral BC. Patients who are eligible proceed BCS. After BCS, patients who showed BpCR are enrolled with omission of SLNB. Patients with no BpCR proceed with routine axillary surgery. The assumption for acceptable 5-year RFS ≥84% is based on previous study findings. The calculated total case number for per- protocol analysis is N=178. Primary endpoint: 5-year recurrence free survival. Secondary endpoint: local recurrence free survival, breast cancer specific survival, overall survival, ipsilateral axillary recurrence interval, distant metastasis free survival, contralateral breast free survival, re-operation rate according to breast biopsy after NACT, adverse event, and quality of life. The first patient was enrolled on September 2021. Among 147 patients who screened, 106 patients have been enrolled in January 2022. We plan to complete the target accrual by December 2025. Clinical trial information: NCT04993625 ." @default.
• W4379285891 created "2023-06-05" @default.
• W4379285891 creator A5005022842 @default.
• W4379285891 creator A5028543814 @default.
• W4379285891 creator A5031863352 @default.
• W4379285891 creator A5033852351 @default.
• W4379285891 creator A5038198745 @default.
• W4379285891 creator A5040145953 @default.
• W4379285891 creator A5047422769 @default.
• W4379285891 creator A5052099934 @default.
• W4379285891 creator A5052356151 @default.
• W4379285891 date "2023-06-01" @default.
• W4379285891 modified "2023-09-25" @default.
• W4379285891 title "Selective avoidance of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with HER-2 positive/triple negative breast cancer: Prospective, multi-center, single-arm study (ASLAN)." @default.
• W4379285891 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.tps624" @default.
• W4379285891 hasPublicationYear "2023" @default.
• W4379285891 type Work @default.
• W4379285891 citedByCount "0" @default.
• W4379285891 crossrefType "journal-article" @default.
• W4379285891 hasAuthorship W4379285891A5005022842 @default.
• W4379285891 hasAuthorship W4379285891A5028543814 @default.
• W4379285891 hasAuthorship W4379285891A5031863352 @default.
• W4379285891 hasAuthorship W4379285891A5033852351 @default.
• W4379285891 hasAuthorship W4379285891A5038198745 @default.
• W4379285891 hasAuthorship W4379285891A5040145953 @default.
• W4379285891 hasAuthorship W4379285891A5047422769 @default.
• W4379285891 hasAuthorship W4379285891A5052099934 @default.
• W4379285891 hasAuthorship W4379285891A5052356151 @default.
• W4379285891 hasConcept C121608353 @default.
• W4379285891 hasConcept C126322002 @default.
• W4379285891 hasConcept C143998085 @default.
• W4379285891 hasConcept C188816634 @default.
• W4379285891 hasConcept C2775934546 @default.
• W4379285891 hasConcept C2776694085 @default.
• W4379285891 hasConcept C2777649267 @default.
• W4379285891 hasConcept C2778239845 @default.
• W4379285891 hasConcept C2778292576 @default.
• W4379285891 hasConcept C2780073493 @default.
• W4379285891 hasConcept C2780110267 @default.
• W4379285891 hasConcept C2780212769 @default.
• W4379285891 hasConcept C2780849966 @default.
• W4379285891 hasConcept C2781451048 @default.
• W4379285891 hasConcept C530470458 @default.
• W4379285891 hasConcept C71924100 @default.
• W4379285891 hasConceptScore W4379285891C121608353 @default.
• W4379285891 hasConceptScore W4379285891C126322002 @default.
• W4379285891 hasConceptScore W4379285891C143998085 @default.
• W4379285891 hasConceptScore W4379285891C188816634 @default.
• W4379285891 hasConceptScore W4379285891C2775934546 @default.
• W4379285891 hasConceptScore W4379285891C2776694085 @default.
• W4379285891 hasConceptScore W4379285891C2777649267 @default.
• W4379285891 hasConceptScore W4379285891C2778239845 @default.
• W4379285891 hasConceptScore W4379285891C2778292576 @default.
• W4379285891 hasConceptScore W4379285891C2780073493 @default.
• W4379285891 hasConceptScore W4379285891C2780110267 @default.
• W4379285891 hasConceptScore W4379285891C2780212769 @default.
• W4379285891 hasConceptScore W4379285891C2780849966 @default.
• W4379285891 hasConceptScore W4379285891C2781451048 @default.
• W4379285891 hasConceptScore W4379285891C530470458 @default.
• W4379285891 hasConceptScore W4379285891C71924100 @default.
• W4379285891 hasIssue "16_suppl" @default.
• W4379285891 hasLocation W43792858911 @default.
• W4379285891 hasOpenAccess W4379285891 @default.
• W4379285891 hasPrimaryLocation W43792858911 @default.
• W4379285891 hasRelatedWork W2161568138 @default.
• W4379285891 hasRelatedWork W2358175358 @default.
• W4379285891 hasRelatedWork W2363804192 @default.
• W4379285891 hasRelatedWork W2367105124 @default.
• W4379285891 hasRelatedWork W2387313003 @default.
• W4379285891 hasRelatedWork W2978037657 @default.
• W4379285891 hasRelatedWork W3003824342 @default.
• W4379285891 hasRelatedWork W3042648814 @default.
• W4379285891 hasRelatedWork W3092178973 @default.
• W4379285891 hasRelatedWork W3095199482 @default.
• W4379285891 hasVolume "41" @default.
• W4379285891 isParatext "false" @default.
• W4379285891 isRetracted "false" @default.
• W4379285891 workType "article" @default.